Tag: Roche’s Tecentriq-chemotherapy combo now approved for treating aggressive type of lung cancer
Roche’s Tecentriq-chemotherapy combo now approved for treating aggressive type of lung cancer
The Singaporean Health Sciences Authority (HAS) has recently approved of global pharmaceutical giant Roche’s new immunotherapy treatment: Tecentriq® (Atezolizumab) will be used as first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC), after reports showed that the cancer […]